Therapeutic | Inebilizumab |
Target | CD19 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS |
Light Chain | EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | POTELLIGENT Technology |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | Cellective Therapeutics%3BMedImmune |
Conditions Approved | Neuromyelitis optica |
Conditions Active | Autoimmune disorders%3BMyasthenia gravis%3BRenal transplant rejection |
Conditions Discontinued | B-cell lymphoma%3BChronic lymphocytic leukaemia%3BDiffuse large B-cell lymphoma%3BFollicular lymphoma%3BMultiple myeloma%3BMultiple sclerosis%3BSystemic scleroderma |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]